Hydroxyprogesterone heptanoate benzilic acid hydrazone
 | |
| Clinical data | |
|---|---|
| Other names | Hydroxyprogesterone heptanoate benziloylhydrazone; OHPHBH; Hydroxyprogesterone enanthate benzilic acid hydrazone; 17α-Hydroxyprogesterone 17α-heptanoate 3-benzilic acid hydrazone |
| Routes of administration | Intramuscular injection |
| Drug class | Progestin; Progestogen; Progestogen ester |
| Identifiers | |
| CAS Number | |
| Chemical and physical data | |
| Formula | C42H54N2O5 |
| Molar mass | 666.903 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Hydroxyprogesterone heptanoate benzilic acid hydrazone (OHPHBH), also known as 17α-hydroxyprogesterone 17α-heptanoate 3-benzilic acid hydrazone, is a progestin medication which was never marketed.[1][2] It is the C3 benzilic acid hydrazone of hydroxyprogesterone heptanoate (OHPH).[1][2] The medication has a longer duration of action than OHPH when administered by subcutaneous injection in animals.[1][2]
See also
- Testosterone enantate benzilic acid hydrazone
- List of progestogen esters § Esters of 17α-hydroxyprogesterone derivatives
References
- ^ a b c Ralph I. Dorfman (3 February 2016). Bioassay. Elsevier. pp. 252–. ISBN 978-1-4832-7276-4.
- ^ a b c Gleason CH, Parker JM (1959). "The duration of activity of the benziloyl hydrazones of testosterone-17-heptanoate, estrone-3-heptanoate and 17α-hydroxy-progesterone-17-heptanoate". Endocrinology. 65 (3): 508–511. doi:10.1210/endo-65-3-508. ISSN 0013-7227. PMID 13828402.